Neuroprotection by Mucuna pruriens in Neurodegenerative Diseases.
Alzheimer’s disease
Amyotrophic lateral sclerosis
Medicinal plant
Mucuna pruriens
Neuroprotection
Parkinson’s disease
Journal
Neurochemical research
ISSN: 1573-6903
Titre abrégé: Neurochem Res
Pays: United States
ID NLM: 7613461
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
31
12
2021
accepted:
24
03
2022
revised:
22
03
2022
pubmed:
6
4
2022
medline:
25
6
2022
entrez:
5
4
2022
Statut:
ppublish
Résumé
The medicinal plant Mucuna pruriens (Fabaceae) is widely known for its anti-oxidative and anti-inflammatory properties. It is a well-established drug in Ayurveda and has been widely used for the treatment of neurological disorders and male infertility for ages. The seeds of the plant have potent medicinal value and its extract has been tested in different models of neurodegenerative diseases, especially Parkinson's disease (PD). Apart from PD, Mucuna pruriens is now being studied in models of other nervous systems disorders such as Alzheimer's disease (AD), Amyotrophic lateral sclerosis (ALS) and stroke because of its neuroprotective importance. This review briefly discusses the pathogenesis of PD, AD, ALS and stroke. It aims to summarize the medicinal importance of Mucuna pruriens in treatment of these diseases, and put forward the potential targets where Mucuna pruriens can act for therapeutic interventions. In this review, the effect of Mucuna pruriens on ameliorating the neurodegeneration evident in PD, AD, ALS and stroke is briefly discussed. The potential targets for neuroprotection by the plant are delineated, which can be studied further to validate the hypothesis regarding the use of Mucuna pruriens for the treatment of these diseases.
Identifiants
pubmed: 35380400
doi: 10.1007/s11064-022-03591-3
pii: 10.1007/s11064-022-03591-3
doi:
Substances chimiques
Plant Extracts
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1816-1829Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Mannangatti P, Naidu KN (2016) Indian herbs for the treatment of neurodegenerative disease. In: Essa Mohamed, Akbar Mohammed, Guillemin Gilles (eds) The Benefits of Natural Products for Neurodegenerative Diseases, M. Springer, Cham, pp 323–336
doi: 10.1007/978-3-319-28383-8_17
Mishra LC (ed) (2003) Scientific basis for Ayurvedic therapies. Routledge, London
Pathania R, Chawla P, Khan H, Kaushik R, Khan MA (2020) An assessment of potential nutritive and medicinal properties of Mucuna pruriens: a natural food legume. 3 Biotech. 10:1–5
doi: 10.1007/s13205-020-02253-x
Suresh S, Prithiviraj E, Lakshmi NV, Ganesh MK, Ganesh L, Prakash S (2013) Effect of Mucuna pruriens (Linn.) on mitochondrial dysfunction and DNA damage in epididymal sperm of streptozotocin induced diabetic rat. Journal of Ethnopharmacology. 145(1):32–41
pubmed: 23103904
doi: 10.1016/j.jep.2012.10.030
Duke JA (2008) Duke’s handbook of medicinal plants of Latin America. CRC Press, London
doi: 10.1201/9781420043174
Jayaweera DM (1982) Medicinal plants used in Ceylon Part 3(442):161
Sathiyanarayanan L, Arulmozhi S (2007) Mucuna pruriens Linn.- a comprehensive review. Pharmacognosy Rev 1(1):157–162
Bhaskar A, Nithya V, Vidhya VG (2011) Phytochemical evaluation by GC-MS and antihyperglycemic activity of Mucuna pruriens on streptozotocin induced diabetes in rats. J Chem Pharm Res 3(5):689–696
Rakesh B, Praveen N. Chapter-10 biotechnological approaches for the production of l-DOPA: a novel and potent anti-Parkinson’s drug from Mucuna pruriens (L.) DC. Chief Editor. 2020;179.
Amin KY, Khan MN, Zillur-Rehman S, Khan NA (1996) Sexual function improving effect of Mucuna pruriens in sexually normal male rats. Fitoterapia (Milano). 67(1):53–8
Adepoju GK, Odubena OO (2009) Effect of Mucuna pruriens on some haematological and biochemical parameters. J Med Plants Res 3(2):73–76
Yadav SK, Prakash J, Chouhan S, Singh SP (2013) Mucuna pruriens seed extract reduces oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in paraquat-induced Parkinsonian mouse model. Neurochem Int 62(8):1039–1047
pubmed: 23562769
doi: 10.1016/j.neuint.2013.03.015
Dhanasekaran M, Tharakan B, Manyam BV (2008) Antiparkinson drug–Mucuna pruriens shows antioxidant and metal chelating activity. Phytother Res 22(1):6–11
pubmed: 18064727
doi: 10.1002/ptr.2109
Pushpalatha B, Venumadhav N, Swathi M, Raju BA (2013) Neuroprotective effect of resveratrol against scopolamine-induced cognitive impairment and oxidative stress in rats. Arch Biol Sci 65(4):1381–1386
doi: 10.2298/ABS1304381P
Fothergill-Misbah N, Maroo H, Cham M, Pezzoli G, Walker R, Cilia R (2020) Could Mucuna pruriens be the answer to Parkinson’s disease management in sub-Saharan Africa and other low-income countries worldwide? Parkinsonism Relat Disord 1(73):3–7
doi: 10.1016/j.parkreldis.2020.03.002
Diamond SG, Marchkham CH, Hoehn MM, McDowell FH, Muenter MD (1987) Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann Neurol 22(1):8–12
pubmed: 3631925
doi: 10.1002/ana.410220105
Rai SN, Birla H, Singh SS, Zahra W, Patil RR, Jadhav JP, Gedda MR, Singh SP (2017) Mucuna pruriens protects against MPTP intoxicated neuroinflammation in Parkinson’s disease through NF-κB/pAKT signaling pathways. Front Aging Neurosci 19(9):421
doi: 10.3389/fnagi.2017.00421
Rai SN, Birla H, Zahra W, Singh SS, Singh SP (2017) Immunomodulation of Parkinson’s disease using Mucuna pruriens (Mp). J Chem Neuroanat 1(85):27–35
doi: 10.1016/j.jchemneu.2017.06.005
Javed H, Nagoor Meeran MF, Azimullah S, Adem A, Sadek B, Ojha SK (2019) Plant extracts and phytochemicals targeting α-synuclein aggregation in Parkinson’s disease models. Front Pharmacol 19(9):1555
doi: 10.3389/fphar.2018.01555
Rasheed MS, Tripathi MK, Mishra AK, Shukla S, Singh MP (2016) Resveratrol protects from toxin-induced parkinsonism: plethora of proofs hitherto petty translational value. Molecular neurobiology. 53(5):2751–60
doi: 10.1007/s12035-015-9124-3
Gelders G, Baekelandt V, Van der Perren A (2018) Linking neuroinflammation and neurodegeneration in Parkinson’s disease. J Immunol Res 2018:1–12
doi: 10.1155/2018/4784268
Ghiglieri V, Calabrese V, Calabresi P (2018) Alpha-synuclein: from early synaptic dysfunction to neurodegeneration. Front Neurol 4(9):295
doi: 10.3389/fneur.2018.00295
Hu Q, Wang G (2016) Mitochondrial dysfunction in Parkinson’s disease. Transl Neurodegen 5(1):1–8
doi: 10.1186/s40035-015-0049-6
McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P (2001) Failure of the ubiquitin–proteasome system in Parkinson’s disease. Nat Rev Neurosci 2(8):589–594
pubmed: 11484002
doi: 10.1038/35086067
Rao RV, Bredesen DE (2004) Misfolded proteins, endoplasmic reticulum stress and neurodegeneration. Curr Opin Cell Biol 16(6):653–662
pubmed: 15530777
pmcid: 3970707
doi: 10.1016/j.ceb.2004.09.012
Olson KE, Gendelman HE (2016) Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson’s disease. Curr Opin Pharmacol 1(26):87–95
doi: 10.1016/j.coph.2015.10.006
Shih RH, Wang CY, Yang CM (2015) NF-kappaB signaling pathways in neurological inflammation: a mini review. Front Mol Neurosci 18(8):77
Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8(1):57–69
pubmed: 17180163
doi: 10.1038/nrn2038
Suzumura A, Takeuchi H, Zhang G, Kuno R, Mizuno T (2006) Roles of glia-derived cytokines on neuronal degeneration and regeneration. Ann N Y Acad Sci 1088(1):219–229
pubmed: 17192568
doi: 10.1196/annals.1366.012
Shahidi F (2000) Antioxidants in food and food antioxidants. Food Nahrung 44(3):158–163
pubmed: 10907235
doi: 10.1002/1521-3803(20000501)44:3<158::AID-FOOD158>3.0.CO;2-L
Levites Y, Weinreb O, Maor G, Youdim MB, Mandel S (2001) Green tea polyphenol (–)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 78(5):1073–1082
pubmed: 11553681
doi: 10.1046/j.1471-4159.2001.00490.x
de Carvalho MC, Barca FN, Agnez-Lima LF, de Medeiros SR (2003) Evaluation of mutagenic activity in an extract of pepper tree stem bark (Schinus terebinthifolius Raddi). Environ Mol Mutagen 42(3):185–191
pubmed: 14556225
doi: 10.1002/em.10183
Ferreira-Machado SC, Rodrigues MP, Nunes AP, Dantas FJ, De Mattos JC, Silva CR, Moura EG, Bezerra RJ, Caldeira-de-Araujo A (2004) Genotoxic potentiality of aqueous extract prepared from Chrysobalanus icaco L. leaves. Toxicol Lett 151(3):481–7
pubmed: 15261992
doi: 10.1016/j.toxlet.2004.03.014
Manyam BV, Dhanasekaran M, Hare TA (2004) Effect of antiparkinson drug HP-200 (Mucuna pruriens) on the central monoaminergic neurotransmitters. Phytother Res 18(2):97–101
pubmed: 15022157
doi: 10.1002/ptr.1407
Kim WS, Kågedal K, Halliday GM (2014) Alpha-synuclein biology in Lewy body diseases. Alzheimer’s Res Ther 6(5):1–9
Luk KC, Kehm V, Carroll J, Zhang B, O’Brien P, Trojanowski JQ, Lee VM (2012) Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338(6109):949–953
pubmed: 23161999
pmcid: 3552321
doi: 10.1126/science.1227157
Kum WF, Durairajan SS, Bian ZX, Man SC, Lam YC, Xie LX, Lu JH, Wang Y, Huang XZ, Li M (2011) Treatment of idiopathic Parkinson’s disease with traditional Chinese herbal medicine: a randomized placebo-controlled pilot clinical study. Evidence-Based Complementary Alternative Med 1:2011
Amer DA, Irvine GB, El-Agnaf OM (2006) Inhibitors of α-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson’s disease and related disorders. Exp Brain Res 173(2):223–233
pubmed: 16733698
doi: 10.1007/s00221-006-0539-y
Vassallo N (2008) Polyphenols and health: new and recent advances. Nova Publishers, New York
Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A, Wanker EE (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15(6):558
pubmed: 18511942
doi: 10.1038/nsmb.1437
Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K, Wanker EE (2010) EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity. Proc Natl Acad Sci 107(17):7710–7715
pubmed: 20385841
pmcid: 2867908
doi: 10.1073/pnas.0910723107
Zhu M, Rajamani S, Kaylor J, Han S, Zhou F, Fink AL (2004) The flavonoid baicalein inhibits fibrillation of α-synuclein and disaggregates existing fibrils. J Biol Chem 279(26):26846–26857
pubmed: 15096521
doi: 10.1074/jbc.M403129200
Rao JN, Dua V, Ulmer TS (2008) Characterization of α-synuclein interactions with selected aggregation-inhibiting small molecules. Biochemistry 47(16):4651–4656
pubmed: 18366183
doi: 10.1021/bi8002378
Ono K, Yamada M (2006) Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for α-synuclein fibrils in vitro. J Neurochem 97(1):105–115
pubmed: 16524383
doi: 10.1111/j.1471-4159.2006.03707.x
Masuda M, Suzuki N, Taniguchi S, Oikawa T, Nonaka T, Iwatsubo T, Hisanaga SI, Goedert M, Hasegawa M (2006) Small molecule inhibitors of α-synuclein filament assembly. Biochemistry 45(19):6085–6094
pubmed: 16681381
doi: 10.1021/bi0600749
Hong DP, Fink AL, Uversky VN (2008) Structural characteristics of α-synuclein oligomers stabilized by the flavonoid baicalein. J Mol Biol 383(1):214–223
pubmed: 18775438
pmcid: 2573395
doi: 10.1016/j.jmb.2008.08.039
Meng X, Munishkina LA, Fink AL, Uversky VN (2009) Molecular mechanisms underlying the flavonoid-induced inhibition of α-synuclein fibrillation. Biochemistry 48(34):8206–8224
pubmed: 19634918
doi: 10.1021/bi900506b
Ren R, Shi C, Cao J, Sun Y, Zhao X, Guo Y, Wang C, Lei H, Jiang H, Ablat N, Xu J (2016) Neuroprotective effects of a standardized flavonoid extract of safflower against neurotoxin-induced cellular and animal models of Parkinson’s disease. Sci Rep 6(1):1–3
doi: 10.1038/s41598-016-0001-8
Cheon SM, Jang I, Lee MH, Kim DK, Jeon H, Cha DS (2017) Sorbus alnifolia protects dopaminergic neurodegeneration in Caenorhabditis elegans. Pharm Biol 55(1):481–486
pubmed: 27937005
doi: 10.1080/13880209.2016.1251468
Briffa M, Ghio S, Neuner J, Gauci AJ, Cacciottolo R, Marchal C, Caruana M, Cullin C, Vassallo N, Cauchi RJ (2017) Extracts from two ubiquitous Mediterranean plants ameliorate cellular and animal models of neurodegenerative proteinopathies. Neurosci Lett 18(638):12–20
doi: 10.1016/j.neulet.2016.11.058
Caruana M, Högen T, Levin J, Hillmer A, Giese A, Vassallo N (2011) Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds. FEBS Lett 585(8):1113–1120
pubmed: 21443877
doi: 10.1016/j.febslet.2011.03.046
Hussain G, Manyam BV (1997) Mucuna pruriens proves more effective than L-DOPA in Parkinson’s disease animal model. Phytother Res 11:419–423
doi: 10.1002/(SICI)1099-1573(199709)11:6<419::AID-PTR120>3.0.CO;2-Q
Yadav SK, Rai SN, Singh SP (2017) Mucuna pruriens reduces inducible nitric oxide synthase expression in Parkinsonian mice model. J Chem Neuroanat 1(80):1
doi: 10.1016/j.jchemneu.2016.11.009
Mariani E, Polidori MC, Cherubini A, Mecocci P (2005) Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B 827(1):65–75
doi: 10.1016/j.jchromb.2005.04.023
Modi KP, Patel NM, Goyal RK (2008) Estimation of L-Dopa from Mucuna pruriens L INN and formulations containing M. pruriens by HPTLC Method. Chem Pharm Bull 56(3):357–9
doi: 10.1248/cpb.56.357
Prakash A, Niranjan SK, Tewari D (2001) Some nutritional properties of the seeds of three Mucuna species. Int J Food Sci Nutr 52(1):79–82
pubmed: 11225181
doi: 10.1080/09637480020027264
Ghosal S, Singh S, Bhattacharya SK (1971) Alkaloids of Mucuna pruriens chemistry and pharmacology. Planta Med 19(01):279–284
doi: 10.1055/s-0028-1099642
Kumar A, Ahmad I, Shukla S, Singh BK, Patel DK, Pandey HP, Singh C (2010) Effect of zinc and paraquat co-exposure on neurodegeneration: modulation of oxidative stress and expression of metallothioneins, toxicant responsive and transporter genes in rats. Free Radical Res 44(8):950–965
doi: 10.3109/10715762.2010.492832
Yadav SK, Prakash J, Chouhan S, Westfall S, Verma M, Singh TD, Singh SP (2014) Comparison of the neuroprotective potential of Mucuna pruriens seed extract with estrogen in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced PD mice model. Neurochem Int 1(65):1–3
doi: 10.1016/j.neuint.2013.12.001
Manyam BV, Dhanasekaran M, Hare TA (2004) Neuroprotective effects of the antiparkinson drug Mucuna pruriens. Phytother Res 18(9):706–712
pubmed: 15478206
doi: 10.1002/ptr.1514
Katzenschlager R, Evans A, Manson A, Patsalos PN, Ratnaraj N, Watt H, Timmermann L, Van der Giessen R, Lees AJ (2004) Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psych 75(12):1672–1677
doi: 10.1136/jnnp.2003.028761
Prakash J, Yadav SK, Chouhan S, Prakash S, Singh SP (2013) Synergistic effect of Mucuna pruriens and Withania somnifera in a paraquat induced Parkinsonian mouse model. Adv Biosci Biotechnol 4(11):1
doi: 10.4236/abb.2013.411A2001
Lieu CA, Kunselman AR, Manyam BV, Venkiteswaran K, Subramanian T (2010) A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias. Parkinsonism Relat Disord 16(7):458–465
pubmed: 20570206
pmcid: 2909380
doi: 10.1016/j.parkreldis.2010.04.015
Lieu CA, Venkiteswaran K, Gilmour TP, Rao AN, Petticoffer AC, Gilbert EV, Deogaonkar M, Manyam BV, Subramanian T (2012) The antiparkinsonian and antidyskinetic mechanisms of Mucuna pruriens in the MPTP-treated nonhuman primate. Evidence-Based Complementary Alternative Med 1:2012
Uhegbu FO, Elekwa IF, Ukoha C (2005) Comparative efficacy of crude aqueous extract of Mangiferea Indica, Carica Papaya and Sulphadoxine Pyrimethamine on mice infested with malaria parasite in vivo. Global J Pure Appl Sci 11(3):74–76
Nagashayana N, Sankarankutty P, Nampoothiri MR, Mohan PK, Mohanakumar KP (2000) Association of L-DOPA with recovery following Ayurveda medication in Parkinson’s disease. J Neurol Sci 176(2):124–127
pubmed: 10930594
doi: 10.1016/S0022-510X(00)00329-4
Mohapatra S, Ganguly P, Singh R, Katiyar CK (2020) Estimation of Levodopa in the Unani Drug Mucuna pruriens Bak. and its marketed formulation by high-performance thin-layer chromatographic technique. J AOAC Int. 103(3):678–83
pubmed: 31540588
doi: 10.5740/jaoacint.19-0288
Saranya G, Jiby MV, Jayakumar KS, Pillai PP, Jayabaskaran C (2020) L-DOPA synthesis in Mucuna pruriens (L.) DC. is regulated by polyphenol oxidase and not CYP 450/tyrosine hydroxylase: an analysis of metabolic pathway using biochemical and molecular markers. Phytochemistry. 178:112467
pubmed: 32771675
doi: 10.1016/j.phytochem.2020.112467
Yadav SK, Rai SN, Singh SP (2016) Mucuna pruriens shows neuroprotective effect by inhibiting apoptotic pathways of dopaminergic neurons in the paraquat mouse model of parkinsonism. Eur J Pharmaceut Med Res 3:441–451
Rai SN, Dilnashin H, Birla H, Singh SS, Zahra W, Rathore AS, Singh BK, Singh SP (2019) The role of PI3K/Akt and ERK in neurodegenerative disorders. Neurotox Res 35(3):775–795
pubmed: 30707354
doi: 10.1007/s12640-019-0003-y
Rai SN, Yadav SK, Singh D, Singh SP (2016) Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model. J Chem Neuroanat 1(71):41–49
doi: 10.1016/j.jchemneu.2015.12.002
Rai SN, Zahra W, Singh SS, Birla H, Keswani C, Dilnashin H, Rathore AS, Singh R, Singh RK, Singh SP (2019) Anti-inflammatory activity of ursolic acid in MPTP-induced parkinsonian mouse model. Neurotox Res 36(3):452–462
pubmed: 31016688
doi: 10.1007/s12640-019-00038-6
Zahra W, Rai SN, Birla H, Singh SS, Rathore AS, Dilnashin H, Singh R, Keswani C, Singh RK, Singh SP (2020) Neuroprotection of rotenone-induced Parkinsonism by ursolic acid in PD mouse model. CNS Neurol Disord-Drug Targets 19(7):527–540
pubmed: 32787765
doi: 10.2174/1871527319666200812224457
Adi YK, Widayanti R, Pangestiningsih TW (2018) n-Propanol extract of boiled and fermented koro benguk (Mucuna pruriens seed) shows a neuroprotective effect in paraquat dichloride-induced Parkinson’s disease rat model. Vet world 11(9):1250
pubmed: 30410229
pmcid: 6200579
doi: 10.14202/vetworld.2018.1250-1254
Poddighe S, De Rose F, Marotta R, Ruffilli R, Fanti M, Secci PP, Mostallino MC, Setzu MD, Zuncheddu MA, Collu I, Solla P (2014) Mucuna pruriens (velvet bean) rescues motor, olfactory, mitochondrial and synaptic impairment in PINK1 B9 drosophila melanogaster genetic model of Parkinson’s disease. PLoS One. 9(10):e110802
pubmed: 25340511
pmcid: 4207759
doi: 10.1371/journal.pone.0110802
Solari P, Maccioni R, Marotta R, Catelani T, Debellis D, Baroli B, Peddio S, Muroni P, Kasture S, Solla P, Stoffolano JG Jr (2018) The imbalance of serotonergic circuitry impairing the crop supercontractile muscle activity and the mitochondrial morphology of PD PINK1B9 Drosophila melanogaster are rescued by Mucuna pruriens. J Insect Physiol 1(111):32–40
doi: 10.1016/j.jinsphys.2018.10.007
Johnson SL, Park HY, DaSilva NA, Vattem DA, Ma H, Seeram NP (2018) Levodopa-reduced Mucuna pruriens seed extract shows neuroprotective effects against Parkinson’s disease in murine microglia and human neuroblastoma cells, Caenorhabditis elegans, and Drosophila melanogaster. Nutrients 10(9):1139
pmcid: 6164394
doi: 10.3390/nu10091139
Cilia R, Laguna J, Cassani E, Cereda E, Raspini B, Barichella M, Pezzoli G (2018) Daily intake of Mucuna pruriens in advanced Parkinson’s disease: a 16-week, noninferiority, randomized, crossover, pilot study. Parkinsonism Relat Disord 1(49):60–66
doi: 10.1016/j.parkreldis.2018.01.014
Liu W, Ma H, DaSilva NA, Rose KN, Johnson SL, Zhang L, Wan C, Dain JA, Seeram NP (2016) Development of a neuroprotective potential algorithm for medicinal plants. Neurochem Int 1(100):164–177
doi: 10.1016/j.neuint.2016.09.014
Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA (2005) Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25(34):7709–7717
pubmed: 16120771
pmcid: 6725245
doi: 10.1523/JNEUROSCI.2177-05.2005
Ittner LM, Götz J (2011) Amyloid-β and tau—a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci 12(2):67–72
doi: 10.1038/nrn2967
Alzheimer’s Association (2015) 2015 Alzheimer’s disease facts and figures. Alzheimers Dement 11(3):332–384
doi: 10.1016/j.jalz.2015.02.003
Citron M (2010) Alzheimer’s disease: strategies for disease modification. Nat Rev Drug Discov 9(5):387–398
pubmed: 20431570
doi: 10.1038/nrd2896
Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C (2014) Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol 13(8):788–794
pubmed: 25030513
doi: 10.1016/S1474-4422(14)70136-X
Reitz C, Mayeux R (2014) Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 88(4):640–651
pubmed: 24398425
pmcid: 3992261
doi: 10.1016/j.bcp.2013.12.024
Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443(7113):787–795
pubmed: 17051205
doi: 10.1038/nature05292
Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G (2000) Oxidative stress in Alzheimer’s disease. Biochim et Biophys Acta 1502(1):139–44
doi: 10.1016/S0925-4439(00)00040-5
Christen Y (2000) Oxidative stress and Alzheimer disease. Am J Clin Nutr 71(2):621S-S629
pubmed: 10681270
doi: 10.1093/ajcn/71.2.621s
Choi DY, Lee YJ, Hong JT, Lee HJ (2012) Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer’s disease. Brain Res Bull 87(2–3):144–153
pubmed: 22155297
doi: 10.1016/j.brainresbull.2011.11.014
Palop JJ, Mucke L (2010) Amyloid-β–induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat Neurosci 13(7):812
pubmed: 20581818
pmcid: 3072750
doi: 10.1038/nn.2583
Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS β-amyloid in Alzheimer’s disease. Science 330(6012):1774
pubmed: 21148344
pmcid: 3073454
doi: 10.1126/science.1197623
Li XH, Du LL, Cheng XS, Jiang X, Zhang Y, Lv BL, Liu R, Wang JZ, Zhou XW (2013) Glycation exacerbates the neuronal toxicity of β-amyloid. Cell Death Dis 4(6):e673
pubmed: 23764854
pmcid: 3698547
doi: 10.1038/cddis.2013.180
Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, Münch G (2011) Advanced glycation endproducts and their receptor RAGE in Alzheimer’s disease. Neurobiol Aging 32(5):763–777
pubmed: 19464758
doi: 10.1016/j.neurobiolaging.2009.04.016
Donahue JE, Flaherty SL, Johanson CE, Duncan JA, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V (2006) RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. Acta Neuropathol 112(4):405–415
pubmed: 16865397
doi: 10.1007/s00401-006-0115-3
Ahmed A, Subaiea M, Eid A, Li L, Seeram P, Zawia H (2014) Pomegranate extract modulates processing of amyloid-β precursor protein in an aged Alzheimer’s disease animal model. Curr Alzheimer Res 11(9):834–43
pubmed: 25274111
Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJ, van Gool WA, Hoozemans JJ (2006) The significance of neuroinflammation in understanding Alzheimer’s disease. J Neural Transm 113(11):1685
pubmed: 17036175
doi: 10.1007/s00702-006-0575-6
Chandra V, Pandav R, Dodge HH, Johnston JM, Belle SH, DeKosky ST, Ganguli M (2001) Incidence of Alzheimer’s disease in a rural community in India: the Indo–US study. Neurology 57(6):985–989
pubmed: 11571321
doi: 10.1212/WNL.57.6.985
Yuan T, Ma H, Liu W, Niesen DB, Shah N, Crews R, Rose KN, Vattem DA, Seeram NP (2016) Pomegranate’s neuroprotective effects against Alzheimer’s disease are mediated by urolithins, its ellagitannin-gut microbial derived metabolites. ACS Chem Neurosci 7(1):26–33
pubmed: 26559394
doi: 10.1021/acschemneuro.5b00260
Ashwlayan VD, Singh RA (2011) Reversal effect of Phyllanthus emblica (Euphorbiaceae) Rasayana on memory deficits in mice. Int J Appl Pharm 3:10–15
Rachsee A, Chiranthanut N, Kunnaja P, Sireeratawong S, Khonsung P, Chansakaow S, Panthong A (2021) Mucuna pruriens (L.) DC. seed extract inhibit lipopolysaccharide-induced inflammatory responses in BV2 microglial cells. J Ethnopharmacol 267:113518
pubmed: 33122120
doi: 10.1016/j.jep.2020.113518
Nayak VS, Kumar N, D’Souza AS, Nayak SS, Cheruku SP, Pai KS (2017) The effects of Mucuna pruriens extract on histopathological and biochemical features in the rat model of ischemia. NeuroReport 28(18):1195–1201
pubmed: 28953092
doi: 10.1097/WNR.0000000000000888
Rai SN, Chaturvedi VK, Singh P, Singh BK, Singh MP (2020) Mucuna pruriens in Parkinson’s and in some other diseases: recent advancement and future prospective. 3 Biotech. 10(12):1–1
doi: 10.1007/s13205-020-02532-7
De Rose F, Marotta R, Talani G, Catelani T, Solari P, Poddighe S, Borghero G, Marrosu F, Sanna E, Kasture S, Acquas E (2017) Differential effects of phytotherapic preparations in the hSOD1 Drosophila melanogaster model of ALS. Sci Rep 7(1):1–2
doi: 10.1038/s41598-016-0028-x
Boillée S, Velde CV, Cleveland DW (2006) ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52(1):39–59
pubmed: 17015226
doi: 10.1016/j.neuron.2006.09.018
Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX (1994) Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264(5166):1772–1775
pubmed: 8209258
doi: 10.1126/science.8209258
Ransohoff RM (2016) How neuroinflammation contributes to neurodegeneration. Science 353(6301):777–783
pubmed: 27540165
doi: 10.1126/science.aag2590
Bruijn LI, Miller TM, Cleveland DW (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 21(27):723–749
doi: 10.1146/annurev.neuro.27.070203.144244
Silverman JM, Fernando SM, Grad LI, Hill AF, Turner BJ, Yerbury JJ, Cashman NR (2016) Disease mechanisms in ALS: misfolded SOD1 transferred through exosome-dependent and exosome-independent pathways. Cell Mol Neurobiol 36(3):377–381
pubmed: 26908139
doi: 10.1007/s10571-015-0294-3
Poddighe S, Bhat KM, Setzu MD, Solla P, Angioy AM, Marotta R, Ruffilli R, Marrosu F, Liscia A (2013) Impaired sense of smell in a Drosophila Parkinson’s model. PLoS One. 8(8):e73156
pubmed: 24009736
pmcid: 3757021
doi: 10.1371/journal.pone.0073156
Lu B, Vogel H (2009) Drosophila models of neurodegenerative diseases. Annu Rev Pathol 28(4):315–342
doi: 10.1146/annurev.pathol.3.121806.151529
Kasture S, Mohan M, Kasture V (2013) Mucuna pruriens seeds in treatment of Parkinson’s disease: pharmacological review. Orient Pharm Exp Med 13(3):165–174
doi: 10.1007/s13596-013-0126-2
Maccioni R, Setzu MD, Talani G, Solari P, Kasture A, Sucic S, Porru S, Muroni P, Sanna E, Kasture S, Acquas E (2018) Standardized phytotherapic extracts rescue anomalous locomotion and electrophysiological responses of TDP-43 Drosophila melanogaster model of ALS. Sci Rep 8(1):1
doi: 10.1038/s41598-018-34452-1
Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351(3):602–611
pubmed: 17084815
doi: 10.1016/j.bbrc.2006.10.093
Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314(5796):130–133
pubmed: 17023659
doi: 10.1126/science.1134108
Bose JK, Huang CC, Shen CK (2011) Regulation of autophagy by neuropathological protein TDP-43. J Biol Chem 286(52):44441–44448
pubmed: 22052911
pmcid: 3247982
doi: 10.1074/jbc.M111.237115
Diaper DC, Adachi Y, Sutcliffe B, Humphrey DM, Elliott CJ, Stepto A, Ludlow ZN, Vanden Broeck L, Callaerts P, Dermaut B, Al-Chalabi A (2013) Loss and gain of Drosophila TDP-43 impair synaptic efficacy and motor control leading to age-related neurodegeneration by loss-of-function phenotypes. Hum Mol Genet 22(8):1539–1557
pubmed: 23307927
pmcid: 3605831
doi: 10.1093/hmg/ddt005
Cragnaz L, Klima R, De Conti L, Romano G, Feiguin F, Buratti E, Baralle M, Baralle FE (2015) An age-related reduction of brain TBPH/TDP-43 levels precedes the onset of locomotion defects in a Drosophila ALS model. Neuroscience 17(311):415–421
doi: 10.1016/j.neuroscience.2015.10.037
Feiguin F, Godena VK, Romano G, D’ambrogio A, Klima R, Baralle FE (2009) Depletion of TDP-43 affects Drosophila motoneurons terminal synapsis and locomotive behavior. FEBS Lett 583(10):1586–1592
pubmed: 19379745
doi: 10.1016/j.febslet.2009.04.019